Late-onset pathogens and foci following CAR T-cell therapy. (A) Late-onset infections and (B) long-term foci after (i) anti-BCMA CAR T-cell therapy, (ii) anti-CD19 CAR T-cell therapy, and (iii) overall cohort receiving either CAR T-cell therapy. Respiratory infections increase in the long-term follow-up, whereas urogenital and abdominal foci were observed less frequently. A switch from bacterial infections in the short-term follow-up to mostly viral infections from day 30 to day 360 was observed.